These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25743201)

  • 1. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?
    Olesen JB; Torp-Pedersen C
    Thromb Haemost; 2015 Jun; 113(6):1165-9. PubMed ID: 25743201
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
    Tu HT; Campbell BC; Meretoja A; Churilov L; Lees KR; Donnan GA; Davis SM
    Cerebrovasc Dis; 2013; 36(4):273-80. PubMed ID: 24135809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians' Decision and CHA2DS2-VASc and HAS-BLED Scores.
    Balaghi-Inalou M; Parsa SA; Gachkar L; Andalib S
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):61-64. PubMed ID: 29076078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
    Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?
    Quinn GR; Singer DE; Chang Y; Go AS; Borowsky LH; Fang MC
    Am J Cardiol; 2016 Sep; 118(5):697-9. PubMed ID: 27394408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MY APPROACH to the practical management of anticoagulation in patients with atrial fibrillation.
    Flaker G
    Trends Cardiovasc Med; 2016 Apr; 26(3):292. PubMed ID: 26874917
    [No Abstract]   [Full Text] [Related]  

  • 13. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
    Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A
    Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation.
    Letsas KP; Efremidis M; Giannopoulos G; Deftereos S; Lioni L; Korantzopoulos P; Vlachos K; Xydonas S; Kossyvakis C; Sideris A
    Europace; 2014 Feb; 16(2):202-7. PubMed ID: 23813452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To anticoagulate or not to anticoagulate? - New insights into a common question.
    Fischer AJ; Freisinger E
    Vasa; 2016; 45(2):186. PubMed ID: 27058807
    [No Abstract]   [Full Text] [Related]  

  • 16. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
    Lip GY; Rushton-Smith SK; Goldhaber SZ; Fitzmaurice DA; Mantovani LG; Goto S; Haas S; Bassand JP; Camm AJ; Ambrosio G; Janský P; Al Mahmeed W; Oh S; van Eickels M; Raatikainen P; Steffel J; Oto A; Kayani G; Accetta G; Kakkar AK;
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2 Suppl 1):S12-20. PubMed ID: 25714828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial.
    Kunneman M; Branda ME; Noseworthy PA; Linzer M; Burnett B; Dick S; Spencer-Bonilla G; Fernandez CA; Gorr H; Wambua M; Keune S; Zeballos-Palacios C; Hargraves I; Shah ND; Montori VM
    Trials; 2017 Sep; 18(1):443. PubMed ID: 28962662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
    Sulzgruber P; Wassmann S; Semb AG; Doehner W; Widimsky P; Gremmel T; Kaski JC; Savarese G; Rosano GMC; Borghi C; Kjeldsen K; Torp-Pedersen C; Schmidt TA; Lewis BS; Drexel H; Tamargo J; Atar D; Agewall S; Niessner A
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):171-180. PubMed ID: 31119266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations on stroke prevention for patients having a CHA
    Chao TF; Chen SA; Lip GYH
    Trends Cardiovasc Med; 2019 Oct; 29(7):427-428. PubMed ID: 30833072
    [No Abstract]   [Full Text] [Related]  

  • 20. Stroke in heart failure: atrial fibrillation revisited?
    Pullicino P; Homma S
    J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):1-2. PubMed ID: 20123219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.